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ABSTRACT
This work describes the effectiveness of HDAC-inhibitor (S)-2 towards colorectal 
cancer (CRC) HCT116 cells in vitro by inducing cell cycle arrest and apoptosis, and 
in vivo by contrasting tumour growth in mice xenografts. Among the multifaceted 
drug-induced events described herein, an interesting link has emerged between the 
oncoprotein histone deacetylase HDAC1 and the oncogenic Cancerous Inhibitor of 
Protein Phosphatase 2A (CIP2A) which is overexpressed in several cancers including 
CRCs. HDAC1 inhibition by (S)-2 or specific siRNAs downregulates CIP2A transcription 
in three different CRC cell lines, thus restoring the oncosuppressor phosphatase PP2A 
activity that is reduced in most cancers. Once re-activated, PP2A dephosphorylates 
pGSK-3β(ser9) which phosphorylates β-catenin that remains within the cytosol where 
it undergoes degradation. The decreased amount/activity of β-catenin transcription 
factor prompts cell growth arrest by diminishing c-Myc and cyclin D1 expression and 
abrogating the prosurvival Wnt/β-catenin signaling pathway. These results are the 
first evidence that the inhibition of HDAC1 by (S)-2 downregulates CIP2A transcription 
and unleashes PP2A activity, thus inducing growth arrest and apoptosis in CRC cells.
INTRODUCTION 
Epigenetic changes are reversible rearrangements 
of chromatin capable of modulating gene expression in 
the cell without altering DNA sequence. Acetylation is 
the most widely studied post-translational modification of 
histones [1] and results from the balanced activity of two 
families of enzymes, namely the histone acetyltransferases 
(HATs) and histone deacetylases (HDACs) catalyzing 
acetylation/deacetylation of histones, respectively, and 
thereby providing DNA accessibility to transcription 
factors [2–5]. 
In cancer cells HDACs are typically overexpressed 
[6–9] and represent, therefore, the targets for diverse 
natural/synthetic compounds acting as HDAC-inhibitors 
(HDACis) [10–12]. Some of them have successfully been 
used in the clinic, either alone or in combination with 
conventional cytotoxics, as potent antineoplastic drugs 
to support current therapy [10, 11, 13]. Indeed, HDACis 
have proven effective in promoting cell cycle arrest 
and apoptosis in various types of tumours through the 
generation of reactive oxygen species, activation of caspase 
cascade, disruption of mitochondrial integrity, increase in 
autophagy [10], and suppression of pro-survival pathways 
[14, 15]. These events were at least in part mediated by 
acetylation of histones and nonhistone key regulatory 
proteins [16] including p53, GATA1, GATA2, retinoic acid 
receptor, NF-kB and cytoskeletal proteins like a-tubulin 
[17–19].
Previously, we described a new series of HDACis 
generated through the hybridization of 1,4-benzodiazepine 
(BDZ) ring with SAHA or oxamflatin [20] yielding 
compounds that displayed powerful anticancer properties 
against human malignant cells of acute myeloid leukemia 
[21], prostate adenocarcinoma [22], metastatic melanoma 
[15] and, notably, were safe to normal mice in vivo up to 
high dosages [15, 21].
The study herein aimed at evaluating the 
effectiveness of a specific HDACi, termed (S)-2, towards 
human colorectal cancer (CRC) cells HCT116 (and 
partly also HT-29 and HCT8) in vitro and at describing 
mechanisms underlying drug-induced cell growth arrest 
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and apoptosis. Moreover, the drug showed to be also 
effective in vivo by contrasting HCT116 cell growth in 
mice xenografts.
Our results point to a crucial involvement of 
serine/threonine phosphatases and, in particular, of their 
physiological inhibitors, as mediators of anticancer 
properties of (S)-2 in CRC cells. Furthermore, these 
findings disclose a new role for HDAC1 in governing 
transcription of the oncogenic Cancerous Inhibitor of 
Protein Phosphatase 2A (CIP2A) that is known to be 
overexpressed in numerous cancers [23, 24] including 
CRCs [25]. To our knowledge, such a molecular link 
between HDAC1 and CIP2A has not been reported 
previously and may help, therefore, to understand the 
widespread anticancer effectiveness of several HDACis, 
including (S)-2, that recognize HDAC1 as a specific target. 
RESULTS
(S)-2 prompts growth arrest and apoptosis in 
HCT116 colorectal carcinoma cells 
The BDZ-hydroxamate hybrid (S)-2 was assayed 
for its HDAC-inhibitory activity by using the human 
colorectal cancer cell line HCT116 as the primary model. 
Western blot analyses showed that incubation of cultures 
with 5 µM (S)-2 enhanced histone H3 acetylation and 
prompted de novo acetylation of both H4 and α-tubulin 
(Figure 1A). These effects were observed as early as at 
6 h and remained steady up to 48 h of treatment, and 
were accompanied by a dose-dependent cell growth 
arrest (Figure 1B). Moreover, typical HCT116 culture 
monolayers underwent morphological changes upon 
incubation with (S)-2 that induced a marked cell 
detachment from the substrate, while the residual attached 
cells displayed a fairly enlarged phenotype (Figure 1C). 
In addition, a 48 h-exposure of HCT116 cultures to 5 mM 
(S)-2 modified cell cycle progression as indicated by 
a nearly three-fold increase of cells arrested in G2/M-
phase relative to control, and a large decrease of cell 
population in S-phase (from about 37% of controls to 
7.2% of treated cultures) (Figure 1D). Besides, about 
half of HCT116 treated cells underwent apoptosis as 
assessed  by flow cytometry at 48 h (Figure 1E, top); 
and consistently, western blots analyses of cell extracts 
from drug-treated cultures showed that (S)-2 caused 
the cleavage of caspase substrate poly(ADP-ribose) 
polymerase (PARP), a well-known pro-apoptotic marker 
(Figure 1E, bottom). Moreover, to clarify mechanisms of 
drug-induced apoptosis in HCT116 cells, we used the pan-
caspase inhibitor Z-VAD-fmk that was added in culture 
at 30 mM concentration just 2 h prior to a 24 h-treatment 
without/with 5 µM (S)-2. The inhibitor abolished (S)-2-
mediated activation of caspase cascade and the cleavage of 
PARP thus indicating that the apoptotic process developed 
through a caspase-dependent pathway (Figure 1F). 
(S)-2 modulates the GSK-3β/β-catenin signaling 
pathway 
An activating mutation of the Wnt/β-catenin 
pathway is a key oncogenic event occurring in almost all 
CRCs [26, 27]. Due to this specific alteration the GSK-
3β-mediated degradation of β-catenin in the cytoplasm is 
inhibited and this allows the protein accumulation of in 
the nucleus where it acts as a transcription factor [28]. It 
seemed interesting, therefore, to explore the effectiveness 
of (S)-2 on GSK-3β/β-catenin signaling pathway in 
HCT116 cells. Immunoblot analyses of total cell extracts 
from cultures incubated up to 48 h with 5 µM (S)-2 
showed a time-dependent decrease in the levels of both 
pGSK-3β(ser9) and active-β-catenin (Figure 2A). The 
evaluation of active β-catenin amounts in total cell lysates 
as well as in the cytosolic and nuclear fractions after 48 
h of treatment proved that the drug caused a significant 
decrease of total active-β-catenin that, however, was 
mainly confined to the nucleus (Figure 2B). Furthermore, 
as c-Myc and cyclin D1 are well-known target oncogenes 
of β-catenin transcriptional activity [26, 28] we monitored 
their expression following treatment without/with 5 µM 
(S)-2 for 24 h and 48 h, and observed a significant drug-
induced decrease of mRNA and protein levels (Figure 2C, 
top and bottom panel, respectively).
PP2A, rather than PP1, plays a role in drug-
mediated GSK-3β dephosphorylation
Once determined that (S)-2 induced GSK-3β 
activation through serine dephosphorylation, it was 
important to identify which serine/threonine protein 
phosphatases could actually be involved. As the bulk of 
cellular serine/threonine phosphatases is represented by 
PP1 and PP2A phosphatases [29], their roles in drug-
mediated pGSK-3β(ser9) dephosphorylation in HCT116 
cells have been investigated with the aid of siRNAs. 
Western blots of lysates of cells transfected with either 
PP1 or PP2A specific siRNAs for 24 h and then incubated 
for additional 24 h without/with 5 µM (S)-2 demonstrated 
that the down-regulation of PP1 and PP2A led to a marked 
increase in pGSK-3β(ser9), but only the down-regulation 
of PP2A was really effective in abrogating drug-induced 
dephosphorylation of pGSK-3β(ser9) (Figure 3A). These 
data were confirmed by experiments carried out with 
Cantharidin, a chemical inhibitor of PP2A [30], that was 
added at 50 µM concentration to HCT116 cell cultures 2 
h prior to a 24 h-treatment without/with (S)-2. Cantharidin 
alone prompted a marked increase in pGSK-3β(ser9) and 
also abolished drug-induced dephosphorylation of pGSK-
3β(ser9) and PARP cleavage thus blocking the apoptotic 
process (Figure 3B). Moreover, further information on 
mechanisms responsible for (S)-2-mediated activation of 
PP2A were provided by monitoring the expression of its 
endogenous cellular inhibitors, i.e. the inhibitor 2 of protein 
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phosphatase 2A (I2PP2A) and the cancerous inhibitor of 
protein phosphatase 2A (CIP2A) [31]. Relative mRNA 
levels of both I2PP2A and CIP2A underwent a significant 
time-dependent decrease upon culture treatment with 
5 µM drug (Figure 3C). Conversely, immunoblot analyses 
showed that while the amount of I2PP2A was steady along 
with the experiment, the CIP2A signal decreased at 15 h 
and more considerably at 24 h thus suggesting that, indeed, 
this was the phosphatase inhibitor playing a major role in 
(S)-2-mediated PP2A activation (Figure 3D). 
Figure 1: (S)-2 induced growth arrest and apoptosis in HCT116 cells. (A) HCT116 cells were incubated for 6, 15, 24 and 48 h 
without/with 5 µM (S)-2 and then processed by Western blot and immunostained for the acetylated histone H3/H4 and nonhistone protein 
acetyl-α-tubulin, while α-tubulin as such was taken as the loading control. (B) Cells (105/well) were seeded in 6-well plates and allowed 
to attach overnight. The day after, increasing amounts of (S)-2 (0, 2.5 and 5 µM) were added to the wells and viable cells (trypan blu-
negative) were counted with the aid of a Bürker chamber at the indicated time points (results were the mean ± SD of experiments done in 
quadruplicate). (C) Phase contrast pictures of companion cultures showed that (S)-2 induced morphological changes and a marked decrease 
in cell density (a typical experiment out of three). (D) For cell cycle distribution HCT116 cultures were treated without/with 5 µM (S)-2 
for 48 h and then incubated with a PI/RNase solution for 30 min at 4°C prior to the flow cytometric analysis. The percentage of cells in 
the different phases of the cell cycle was calculated by the ModFit program and shown in each panel were reproduced in three separate 
experiments. (E) top – Apoptosis in cell cultures treated without/with the drug was also assessed cytofluorimetrically by using the Annexin-
V-Fluos/PI assay and the calculated percentages of four different assays yielded comparable values. (E) bottom – Cell extracts of HCT116 
incubated for the indicated time points with 5 mM (S)-2 were subjected to Western immunoblot analysis of the PARP cleaved fragment; 
GAPDH was the loading control. (F) Cell cultures were pre-incubated for 2 h with the pan-caspase inhibitor Z-VAD-fmk (30 mM) and then 
were treated without/with 5 µM (S)-2 for 24 h. Cell lysates were analyzed by Western immunoblot to detect the cleavage of PARP and of 
caspase 9; GAPDH was the loading control.
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(S)-2-induced downregulation of CIP2A is 
mediated by the inhibition of HDAC1 
The drug-mediated decrease of CIP2A expression 
in HCT116 cells has clearly indicated that HDACs were 
involved in the regulation of this particular gene; and, 
therefore, we evaluated the effects of specific siRNAs 
towards the nuclear histone deacetylase HDAC1 that 
we previously reported to be a sensitive target of (S)-2 
[21]. Western blot analyses showed that HCT116 cells 
treated without/with either 5 µM (S)-2 and/or specific 
HDAC1 siRNA led to a decrease in CIP2A protein signal 
(Figure 4A), hence suggesting that the drug-induced 
decrease of CIP2A could actually develop through the 
inhibition of HDAC1. And, notably, similar changes have 
also been reproduced in different CRC cell lines such as 
HT-29 and HCT8. The direct role of HDAC1 in governing 
CIP2A expression in CRC cells has further been confirmed 
with the aid of a plasmid harboring the human CIP2A full 
length promoter fused with the Luc2 luciferase gene. In 
fact, the downregulation of HDAC1 protein signal by 
specific siRNA led to a significant decrease of mRNA 
levels of Luc2 (Figure 4B) due to the silencing the CIP2A 
promoter in all the three CRC cell lines. 
Figure 2: The effects of (S)-2 on GSK-3β/β-catenin pathway. (A) Cell extracts were analyzed by Western blot to detect phospho-
GSK-3β(ser9), GSK-3β and active-β-Catenin levels; GAPDH was used as the loading control. (B) The total, cytosolic and nuclear extracts 
of HCT116 cells treated for 48 h without/with 5 µM (S)-2 were obtained (see Materials and Methods) and probed for the active-β-Catenin 
levels. Purity of the two subcellular fractions was assessed by the presence of GAPDH and fibrillarin as the markers of the cytosolic and 
nuclear compartment, respectively. (C) mRNA and protein levels of c-Myc and cyclin D1 in HCT116 cells treated without/with 5 µM (S)-2 
for 24 h and 48 h were determined by quantitative real-time PCR (***P ≤ 0.01) and Western blot, respectively.
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Figure 3: PP2A is responsible for drug-mediated pGSK-3β dephosphorylation. (A) HCT116 cells transfected with pool-
siRNAs towards either PP1 or PP2A for 24 h were incubated for additional 24 h without/with 5 mM (S)-2; then cell extracts were analyzed 
by Western immunoblot to detect levels of pGSK-3β(ser9), PP1 and PP2A; α-tubulin was used as the loading control. (B) HCT116 cell 
cultures were pre-incubated for 2 h with 50 µM Cantharidin and then treated without/with 5 µM (S)-2 for 24 h. Cell lysates were analyzed 
by Western blot an probed with specific antibodies against pGSK-3β(ser9) and cleaved PARP fragment; GAPDH was the reference protein. 
(C and D) mRNA and protein levels of either I2PP2A and CIP2A from HCT116 cells treated without/with 5 µM (S)-2 were determined at 
the indicated time points by quantitative real-time PCR (**P ≤ 0.05; ***P ≤ 0.01) and Western blot, respectively. 
Figure 4: Inhibition of HDAC1 induces CIP2A downregulation. (A) HCT116, HT-29 and HCT8 cell cultures were treated 
without/with 5 mM (S)-2 for 24 h or transfected with either HDAC1-specific and scrambled siRNAs for 48 h. Cell lysates were submitted 
to Western immunoblot to detect HDAC1 and CIP2A levels; GAPDH was used as the control protein. (B) Cells were first treated with 
HDAC1-specific siRNA and scrambled siRNA for 48 h, and then co-transfected with either 1082CIP2ALuc-pGL4.10 or pGL4.10 plasmids 
and with pGL4.70 up to 16 h. Luc2 and Renilla mRNA levels were determined by quantitative real-time PCR (**P ≤ 0.05; ***P ≤ 0.01). 
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(S)-2 greatly reduces HCT116 cell proliferation 
in mice xenografts 
To assess the in vivo anticancer effectiveness of (S)-2 
in a xenograft tumor model, HCT116 cells were implanted 
onto both flanks of nude mice (see legend to Figure 5 and 
Materials and Methods for details). A week later, a small 
swelling was perceived under the skin of some of the 
animals which were assumed as positively-xenografted 
mice which were randomized into two groups and then 
injected ip with either the drug or the vehicle (DMSO). 
Treatments were administered three times a week for the 
first two weeks and twice in a row on the last week when 
mice were sacrificed by cervical dislocation. Changes in 
tumour volumes during along with the experiment were 
monitored by measurements with a caliper. Tumour mass 
volumes of (S)-2-treated mice were significantly smaller 
(average ± 30 %) than those of untreated mice (Figure 5A, 
top). Besides, tumour masses of untreated mice were 
hyperemic and underwent ulceration, whereas those of 
drug-treated mice did not burst and remained fairly pale in 
color to suggest that tumour growth elicited only a modest 
angiogenesis (Figure 5A, bottom). 
Immunohistochemistry of tumour specimens was 
performed to determine in vivo effects of (S)-2 (Figure 5B). 
We found that the drug exerted its activity within the 
tumour cells as shown by (a) the presence of acetyl-H3 
and γ-H2AX (the latter denoting drug-induced caspase 
activation and DNA damages) and (b) the marked decrease, 
as compared to untreated mice, in the amount of tumour 
cells positively-stained with MIB-1 (against the nuclear 
marker Ki-67 associated with cell proliferation [32–34]. 
Figure 5: Tumour xenograft. (A) top – Aliquots of HCT116 cell suspension (2.5 × 106 cell/100 µl RPMI) were injected subcutaneously 
in both flanks of male nude mice (see also as Materials and Methods). Positively-xenografted mice were randomized into two groups and then 
injected ip with either the drug or DMSO as the vehicle. Treatments were administered three times a week for the first two weeks and twice 
in a row on the last week when mice were sacrificed by cervical dislocation. Variations in the tumour volumes along with the experiment 
and after the sacrifice were measured by a caliper. (A) bottom – Excised tumours were weighed and volumes were calculated according to 
the formula (length (mm)) × (width (mm)) × (depth (mm)) × p/6. Statistical analyses of changes in tumour volumes (mean ± SD) after 0, 
3, 6 and 8 treatments were as follows: [for untreated mice: #0 (25.7 ± 10.0); #3 (103.3 ± 20.6); #6 (201.7 ± 64.2); #8 (188.6 ± 62.1)] and 
[for treated mice: #0 (28.2 ± 11.7); #3 (76.1 ± 25.5); #6 (128.6 ± 26.5); #8 (142.2 ± 24.7)]. According to these values the drug was capable 
of reducing tumour volumes of about 26.4% (1st week), 36.2% (2nd week) and 24.6% (3rd week), as compared to control. Photographs 
are representative of tumour masses from mice treated with either the vehicle or (S)-2, respectively. (B) top – Immunohistochemistry 
was performed on specimens of human colon cancer xenografts by using primary antibodies against acetyl-H3 and γ-H2AX, and also 
the monoclonal antibody MB-1 that recognizes the nuclear marker Ki-67 associated to cell proliferation (see Materials and Methods) 
followed by a peroxidase-conjugated IgG preparation; 3,3′-diaminobenzidine was employed as the chromogen for development. Slides 
were counterstained with aqueous Meyer hematoxylin and mounted with glycerol for visual inspection and photography. (B) bottom – 
Statistical analyses of data on both top panels of the figure were carried out by Student’s t-test and significant differences between the two 
groups were indicated by the asterisks (**P < 0.05; ***P < 0.01).
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DISCUSSION
The anticancer properties of (S)-2 towards CRC 
cells have been thoroughly described in the previous 
section. Indeed, the drug induced cell cycle arrest and 
caspase-dependent apoptosis in HCT116 cells and also 
proved effective in vivo by contrasting tumour growth 
in mice xenografts. However, moving beyond a plain list 
of all biological and molecular events characterizing the 
anticancer activity of (S)-2 in CRC cells, we would focus 
on a specific result that emerged during this study. HDAC1 
is an oncogenic protein acting as a transcription factor of 
various genes [35] among which, however, CIP2A was 
not included previously. CIP2A is also an oncoprotein 
overexpressed in several cancers including CRCs [25, 36] 
where it inhibits the activity of oncosuppressor PP2A that 
controls cell cycle and apoptosis [36–39]. PP2A inhibition 
suppresses the dephosphorylation of pGSK-3β(ser9), thus 
inhibiting b-catenin degradation and then maintaining 
the activity of canonical Wnt/b-catenin pathway. Results 
herein (see the schematic diagram, Figure 6) show that 
the inhibition of HDAC1, by either (S)-2 or specific 
siRNA, downregulates CIP2A and, therefore, restores 
the activity of PP2A that dephosphorylates pGSK-
3β(ser9). Upon activation, GSK-3β phosphorylates 
b-catenin that remains confined to the cytosol where it 
undergoes degradation. The decreased amount/activity 
of the b-catenin transcription factor induces cell growth 
arrest by diminishing c-Myc and cyclin D1 expression 
and abrogating the prosurvival Wnt/b-catenin signaling 
pathway as well. This is the first time that a direct effect 
of HDAC1 on CIP2A transcription is reported to occur 
in HCT116, HT-29 and HCT8, thus inferring that this 
molecular link might be an original signature shared by 
various types of CRC cells. In this context, the HDACi 
(S)-2 represented the tool capable of unleashing PP2A 
activity by inducing HDAC1-mediated downregulation of 
CIP2A transcription in human colon cancers. 
Figure 6: Schematic diagram of (S)-2-induced growth arrest and apoptosis in colon cancer cells. The oncogenic 
protein HDAC1 acts as a transcription factor for CIP2A that afterward complexes and inactivates PP2A. The latter becomes unable to 
dephosphorylate pGSK-3β(ser9) thus allowing the translocation of β-catenin in the nucleus where it induces the transcription of c-Myc 
and cyclin D1 and, consequently, cell proliferation. The inhibition of HDAC1 by (S)-2 leads to the downregulation of CIP2A expression 
and, thus, restores the activity of PP2A that dephosphorylates pGSK-3β(ser9). The activated kinase GSK-3β phosphorylates β-catenin 
that undergoes degradation by the ubiquitin-proteasome system. The decrease in β-catenin levels downregulates c-Myc and cyclin D1 
expression and, consistent with this, leads to cell growth arrest.
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MATERIALS AND METHODS
Cell culture and treatments
Human colon cancer cells HCT116 (CCL-247, 
ATCC), HT-29 (HTB-38, ATCC) and HCT8 (CCL-244, 
ATCC), have been cultured in RPMI 1640 supplemented 
with 10% fetal bovine serum (FBS, EuroClone, Life 
Science Division, Milan, Italy) and 2 mM L-glutamine 
at 37ºC in 5% CO2 humidified atmosphere. (S)-2 was 
dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, 
ST. Louis, MO, USA) at 0.1 M concentration and stored in 
the dark at room temperature (RT). Working drug solutions 
were obtained by appropriate dilution of the stock solution 
with the culture medium. The amount of DMSO employed 
as vehicle did not interfere with drug biological activities. 
In caspase inhibition experiments Z-VAD-fmk (R&D 
Systems, Minneapolis, MN, USA) was added in culture 
2 h prior to treatment with (S)-2. Cantharidin (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) used to inhibit 
protein phosphatase 2A (PP2A) activity was dissolved 
in DMSO at 0.1 mM final concentration and stored in 
–20ºC; the inhibitor, at the established concentrations, was 
delivered to cultures 2 h prior to treatment. 
Cell cycle analysis and determination of 
apoptosis 
Cell cycle phases were assessed by the propidium 
iodide (PI)-hypotonic citrate method; apoptosis was 
measured by the Annexin-V-Fluos/PI test (Roche 
Molecular Biochemicals, Mannheim, Germany) with the 
aid of Becton Dickinson FACSCalibur System (Becton-
Dickinson, San Jose, CA, USA) [21]. 
Western blotting 
Harvested cells were resuspended in 20 mM 
RIPA buffer (pH 7.4) containing a cocktail of proteinase 
inhibitors (Calbiochem, Merck, Darmstadt, Germany) 
and treated by sonication (Microson XL-2000, Minisonix, 
Farmingdale, NY, USA) to obtain a total protein extract. 
For cytosol-nucleus fractionation, proteins were isolated by 
using the ProteoExtract Subcellular Proteome Extraction 
Kit (Calbiochem) as suggested by the manufacturer. 
Proteins were assayed by the BCA Protein Assay (Thermo 
Scientific, Rockford, IL, USA), analyzed by SDS-
PAGE and western blotting as reported elsewhere [40]. 
Membranes were probed with primary antibodies against 
acetyl-H3, acetyl-H4, active-β-catenin, and PP2A (Upstate 
Biotechnology, Millipore, Bilerica, MA, USA); acetyl-α-
tubulin and α-tubulin (Sigma-Aldrich); GAPDH, cleaved 
PARP, cleaved caspase-9, c-Myc and phospho-GSK-
3β(ser9) (Cell Signaling Technology, Danvers, MA. USA); 
cyclin D1, GSK-3β, I2PP2A, CIP2A and fibrillarin (Santa 
Cruz Biotechnology); suitable peroxidase-conjugated IgG 
preparations (Sigma-Aldrich) were used as secondary 
antibodies; the ECL procedure was employed for 
development. Western immunoblots reported all through 
this work were the mean ± SD of experiments carried out 
in triplicate (unless otherwise specified) and the software 
ImageJ [41] was used for densitometric quantification of 
protein band intensity.
Quantitative real time-PCR analysis
QRT-PCR was performed with reverse transcripted 
cDNA of either untreated or drug-treated cells by using the 
Applied Biosystems 7500HT System according to standard 
protocols. Fold of c-Myc, cyclin D1, I2PP2A and CIP2A 
induction were calculated by the changes of each of their Ct 
values in treated vs. untreated cells and were normalized to 
the 18S rRNA Ct values. Amplification was performed with 
the default PCR setting: 40 cycles of 95°C for 15 sec and of 
60°C for 60 sec using a SYBR Green based detection (SYBR 
Green Master mix; Applied Biosystems, Thermo Fisher 
Scientific, Waltham, MA, USA) and the following primers: 
cyclin D1 forward 5′-CGTGGCCTCTAAGATGAAGG-3′ 
and reverse 5′-GTGTTCAATGAAATCGTGCGG-3′; c-Myc 
forward 5′-TCAAGAGGTGCCACGTCTCC-3′ and reverse 
5′-TCTTGGCAGGATAGTCCTT-3′; I2PP2A forward 5′-CG 
TTCGAGTCAAACGCAGAA-3′ and reverse 5′-CAGCA 
CCTGCATCAGAATGGT-3′; CIP2A forward 5′-TGACCC 
TTCTGCTGCCTACA-3′ and reverse 5′-GCCTTGGCAATC 
CTTTCACA-3′; 18S rRNA forward 5′-CGGCTACCACATC 
AAGGAA-3′ and reverse 5′-GCTGGAATTACCGCGGCT-3.′
siRNAs and plasmids transfection 
In silencing experiments, 2 × 105 cells were seeded 
in 60 mm culture dishes 16 h before transfection with 
siRNAs using 7.5 µl of Lipofectamine RNAiMAX 
(Invitrogen, Thermo Fisher Scientific). PP1 (mix of 
500 pmol of each #105828 targeting PPP1CA, #104504 
targeting PPP1CB and #105829 targeting PPP1CC), PP2A 
(mix of 500 pmol of each #104510 targeting PPP2CA 
and #104717 targeting PPP2CB), HDCA1 (500 pmol of 
#120418) and non-targeting control siRNA (500 pmol of 
#4390844) were from Thermo Fisher Scientific. In over-
expression experiments, 2 × 105 cells were seeded into 
60 mm dishes 16 h before co-transfection with 2.5 μg of 
plasmid 1082CIP2ALuc-pGL4.10 (kind gift of Professor 
Jukka Westermark, University of Turku and Abo Akademi, 
Turku, Finland) [42] or pGL4.10 (as control, Promega, 
Fitchburg, WI, USA) and 2.5 μg pGL4.70 (Promega) 
using 7.5 µl of Lipofectamine LTX (Invitrogen, Thermo 
Fisher Scientific). 
Tumour xenograft model 
Male nude (nu/nu) mice (Harlan Laboratories, Srl, 
San Pietro al Natisone, UD, Italy) were cared for and 
maintained in accordance with applicable European Animal 
Welfare regulations under an approved Institutional Animal 
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Care and Use Protocol in an animal facility at University 
of Florence accredited by the Association for Assessment 
and Accreditation of Laboratory Animal Care. To establish 
subcutaneous tumours, aliquots of HCT116 cell suspension 
(2.5 × 106 cell/100 µl RPMI) were injected subcutaneously 
on both flanks of 24 mice. A week later the tumour mass 
was perceived in 14 mice (out of those originally injected), 
which were then randomized into two equal groups and 
treated with the drug or the vehicle at the established 
times. Changes in tumour volumes during the experiment 
were monitored by regular measurements with a caliper. 
Eventually, mice were killed by cervical dislocation and 
tumours were excised, weighed and their volumes were 
calculated according to the formula (length (mm)) × (width 
(mm)) × (depth (mm)) × p/6.
Immunohistochemistry 
Slides with consecutive 2.5–5 µm sections of paraffin 
embedded tumour masses were first deparaffinized, boiled 
in 1 mM EDTA pH 9 for 15 min and after cooling aspecific 
peroxidases were blocked with 3% H2O2 for 10 min. Then, 
slides were treated according to standard procedures and 
incubated with primary antibody solutions against acetyl-H3 
and γ-H2AX (to denote drug-induced caspase activation 
and DNA damages); and also with the monoclonal 
antibody MIB-1 (recognizing the nuclear marker Ki- 67 
that was associated with cell proliferation) (Dako, 
Glostrup, Danimarca) [33, 34] followed by a peroxidase-
conjugated IgG preparation; 3,3′-diaminobenzidine 
(Zymed Laboratories Inc., South San Francisco, CA, 
USA) was used as the chromogen for development. Slides 
were counterstained with aqueous Meyer hematoxylin 
and mounted with glycerol for visual inspection and 
photography; pictures are representative of four randomly 
chosen microscopic fields (magnification: ×400) and taken 
with the aid of a microscope (Nikon Eclipse, mod. 50i) 
equipped with a digital camera (DS-5 M USB2) (Nikon 
Instruments, Florence, Italy) as described previously [22].
Statistical analysis
The Student′s t-test or one-way analysis of variance 
have been employed to assess statistical significance of 
results. The difference among the values was considered 
significant at P ≤  0.05. 
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